

訂正とお詫び

泌尿器科紀要 **67** : 57-61, 2021

分子標的薬時代における転移性腎癌の腫瘍縮小率が予後に与える影響

諸岡 大地, 高橋 敦, 栗栖 知世, 岡部 洸, 京田 有樹, 高木 良雄

文献の表記に誤りがありました。

以下のように訂正して、お詫び致します。

泌尿器科紀要刊行会

修正前

文献

- 1) Daniel YCH, Wanling X, Meredith MR et al. : Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents : Results From a Large, Multicenter Study. J Clin Oncol **27** : 5794-5799, 2009
- 2) Grunwald V, Dietrich M, Pond GP et al. : Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma : a validation study using the COMPARZ cohort. World J Urol **36** : 1423-1429, 2018
- 6) Kanda Y. : Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant **48** : 452-458, 2013
- 7) Robert JM, Nizar MT, David FM et al. : Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med **378** : 1277-1290, 2018
- 8) Robert JM, Konstantin P, John H et al. : Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med **380** : 1103-1115, 2019
- 9) Michael BA, Elizabeth RP, Igor P et al. : Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer : a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol **19** : 405-415, 2018

修正後

文献

- 1) Heng DY, Xie W, Regan NM et al. : Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study. J Clin Oncol **27** : 5794-5799, 2009
- 2) Grunwald V, Dietrich M, Pond GR : Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma : a validation study using the COMPARZ cohort. World J Urol **36** : 1423-1429, 2018
- 6) Kanda Y : Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant **48** : 452-458, 2013
- 7) Motzer RJ, Tannir NM, McDermott DF et al. : Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med **378** : 1277-1290, 2018
- 8) Motzer RJ, Penkov K, Haanen J et al. : Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med **380** : 1103-1115, 2019
- 9) Rini BI, Plimack ER, Stus V et al. : Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med **380** : 1116-1127, 2019